TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39760815
Drug: AL2846 combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: AL2846 combined with gemcitabine (90 mg and 120 mg)
Study: 39760983
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream 1.5% applied twice daily for 4 weeks, then as needed up to 52 weeks
Study: 39761005
Drug: hSAP (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: hSAP (12.5 μg/g)
Study: 39761829
Drug: Famotidine 20
Normalized name: famotidine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famotidine 20 mg daily
Study: 39762092
Drug: Patch ECG
Normalized name: Ecgonine
DrugBank: Ecgonine (DB01525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patch ECG (ECG247 Smart Heart Sensor)
Study: 39762098
Drug: 300 mg omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg omalizumab administered subcutaneously every 4 weeks (Q4W) for 36 weeks
Study: 39762098
Drug: 300 mg omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 300 mg omalizumab administered subcutaneously every 6 weeks (Q6W) for 36 weeks
Study: 39762098
Drug: Blood samples,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood samples, Weekly Urticaria Activity Score, Chronic Urticaria Quality of Life Questionnaire, Dermatology Life Quality Index
Study: 39762113
Drug: EIMG (Exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: EIMG (Exercise is Medicine Greenville) intervention with a standardised instructional video and a 12-week evidence-informed physical activity programme.
Study: 39762248
Drug: AG-270/S095033 (oral,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG-270/S095033 (oral, potent, reversible inhibitor of MAT2A) administered once daily (QD) or twice daily (BID) in 28-day cycles.
Study: 39762418
Drug: neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment group A)
Study: 39762418
Drug: neoadjuvant chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant chemoradiation + concurrent/sequential PD-1 blockade (experiment group B)
Study: 39762419
Drug: Glecirasib (JAB-21822)
Normalized name: Glecirasib
DrugBank: Glecirasib (DB18744)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecirasib (JAB-21822) administered orally at 800 mg daily
Study: 39762422
Drug: Autogene cevumeran
Normalized name: Autogene cevumeran
DrugBank: Autogene cevumeran (DB17497)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autogene cevumeran monotherapy
Study: 39762740
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg orally disintegrating tablet
Study: 39762879
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid vaginal gel applied for 12 days
Study: 39762879
Drug: Oral metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral metronidazole 500 mg twice daily for seven days
Study: 39763581
Drug: Intravenous levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous levocarnitine (20 mg/kg body weight, infused over 2-3 min after each hemodialysis session for 24 weeks)
Study: 39763581
Drug: Oral levocarnitine
Normalized name: Levocarnitine
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral levocarnitine (500 mg three times daily for 24 weeks)
Study: 39763591
Drug: GV (gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: GV (gel vehicle, placebo)
Study: 39764100
Drug: Preoperative eribulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative eribulin (1.1 mg/m² for three 21-day cycles)
Study: 39764289
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg every 4 weeks on top of standard of care (SOC) treatment (atorvastatin 40 mg/day and ezetimibe 10 mg/day)
Study: 39764289
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SOC) treatment (atorvastatin 40 mg/day and ezetimibe 10 mg/day)
Study: 39764289
Drug: Evolocumab 420
Normalized name: evolocumab 420 in 3.5 ML Cartridge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab 420 mg every 4 weeks
Study: 39764567
Drug: Psilocybin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin therapy (PT) - two 25 mg doses administered orally with psychological support
Study: 39764567
Drug: Escitalopram treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram treatment (ET) - 6-week course with daily doses of 10 mg for three weeks and 20 mg for the subsequent three weeks plus matched psychological support
Study: 39765128
Drug: Pulmonary hypertension
Normalized name: Alyq 20 MG Pulmonary Hypertension Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary hypertension treatments
Study: 39767014
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement consisting of 400 mg of a standardized extract of the persimmon fruit
Study: 39768420
Drug: Dulaglutide and
Normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Dulaglutide and Dapagliflozin combination
Study: 39768420
Drug: DPP-4 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP-4 inhibitor (DPP-4i)
Study: 39769389
Drug: CBA-1205 (afucosylated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBA-1205 (afucosylated humanized antibody against DLK1)
Study: 39769389
Drug: CBA-1205 in
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBA-1205 in combination with lenvatinib
Study: 39770444
Drug: Δ8-THCV after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Δ8-THCV after oral administration
Study: 39770949
Drug: Carnosine 2
Normalized name: ASCORBIC ACID 200 mg / Vitamin D 20 ug / FOLIC ACID 1667 ug / CYANOCOBALAMIN 6 ug / CALCIUM CITRATE 40 mg / IRON PROTEIN SUCCINYLATE 3.6 mg / MAGNESIUM GLYCINATE 8.5 mg / MAGNESIUM OXIDE 60.3 mg / ZINC 8 mg / POLAPREZINC 37.5 mg / CARNOSINE 28 mg ORAL CAPSULE [Remedient]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carnosine 2 g/day for 14 weeks
Study: 39771516
Drug: Novel Lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel Lipid Formulation of Cannabidiol (CBD)
Study: 39771516
Drug: Control (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (standard formulation of CBD)
Study: 39772364
Drug: Gallium-68-labeled fibroblast
Normalized name: Gallium 68 dotatate
DrugBank: Dotatate gallium Ga-68 (DB13925)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gallium-68-labeled fibroblast activation protein inhibitor
Study: 39772606
Drug: Intraarterial tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraarterial tenecteplase up to 4.5 mg
Study: 39772650
Drug: Intravenous fosfomycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fosfomycin
Study: 39772709
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic conditioning (RIC); unilateral upper limb; cuff pressure 200 mm Hg, twice daily for 7 days
Study: 39773014
Drug: Short-acting β-agonist
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting β-agonist (SABA) overuse
Study: 39773112
Drug: PTSD treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTSD treatment strategies
Study: 39773121
Drug: Molecular profiling
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Molecular profiling techniques including DNA, RNA, and T-cell receptor sequencing on SBA tissue samples.
Study: 39773406
Drug: SAC therapists
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAC therapists providing effective treatment tools
Study: 39773433
Drug: PA+Dex (Physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA+Dex (Physical Activity + Dexamethasone 4 mg twice daily for the first 7 days)
Study: 39773460
Drug: GoldiCare intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GoldiCare intervention (redistributing weekly workloads)
Study: 39773562
Drug: Durvalumab (1,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab (1,500 mg, intravenously, every four weeks for 26 cycles max) plus tremelimumab (75 mg, intravenously, every four weeks for 4 cycles max) plus metronomic oral vinorelbine (40 mg, every three weeks)
Study: 39773564
Drug: VB10.16 (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: VB10.16 (3 mg every 3 weeks for 12 weeks, then every 6 weeks) combined with atezolizumab (1,200 mg every 3 weeks for 48 weeks)
Study: 39773801
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (oral follow-up advice and a baseline follow-up card)
Study: 39773831
Drug: Warfarin (international
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (international normalised ratio goal of 2.0-2.5)
Study: 39773848
Drug: MOON (serious
Approvals — FDA: no, EMA: no, PMDA: no
Description: MOON (serious video game) plus standard pharmacological treatment
Study: 39773848
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard pharmacological treatment only)
Study: 39773886
Drug: Aspirin-ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin-ticagrelor
Study: 39773950
Drug: Patch-based PSG
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patch-based PSG
Study: 39774313
Drug: Xalnesiran 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xalnesiran 100 mg (group 1)
Study: 39774313
Drug: Xalnesiran 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xalnesiran 200 mg (group 2)
Study: 39774313
Drug: Xalnesiran 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xalnesiran 200 mg + ruzotolimod 150 mg (group 3)
Study: 39774313
Drug: Xalnesiran 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xalnesiran 200 mg + pegylated interferon alfa-2a 180 μg (group 4)
Study: 39774855
Drug: Intravenous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitamin C treatment
Study: 39774967
Drug: RBI-4000 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBI-4000 single administration at 1 microgram
Study: 39774967
Drug: RBI-4000 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBI-4000 single administration at 10 microgram
Study: 39774967
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of RBI-4000
Study: 39775041
Drug: Optimized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized oral antiparkinsonian therapy
Study: 39775042
Drug: Suraxavir marboxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suraxavir marboxil (40 mg)
Study: 39775195
Drug: Morning bright
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morning bright light therapy (MBLT); 60-min duration; daily over 28-day duration
Study: 39775195
Drug: Sham: deactivated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham: deactivated negative ion generator; 60-min duration; daily over 28-day duration
Study: 39775226
Drug: Topical therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical therapy, methotrexate, adalimumab, secukinumab, guselkumab
Study: 39775763
Drug: Gilteritinib maintenance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gilteritinib maintenance therapy
Study: 39775808
Drug: mHealth-CR (commercially
Approvals — FDA: no, EMA: no, PMDA: no
Description: mHealth-CR (commercially available software on a tablet, remote monitoring, weekly exercise therapist calls for 3 months)
Study: 39775812
Drug: anti-CD22 CAR
Normalized name: Allogenic engineered T cells expressing anti-CD22 CAR UCART22
DrugBank: UCART22 (DB17466)
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-CD22 CAR T-cell (CAR22) therapy
Study: 39775962
Drug: Lavender essential
Normalized name: Nature's Truth Lavender Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender essential oil inhalation for 20 minutes prior to bed for 5 consecutive days
Study: 39775962
Drug: Physiological saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiological saline solution inhalation for 20 minutes prior to bed for 5 consecutive days
Study: 39775962
Drug: Lavender essential
Normalized name: Nature's Truth Lavender Essential Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lavender essential oil inhalation